A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia.

Trial Profile

A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Elobixibat (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Albireo AB
  • Most Recent Events

    • 19 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 19 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top